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Despite recent therapeutic advancements, multiple myeloma
(MM) remains incurable and new therapies are needed,
especially for the treatment of elderly and relapsed/refractory
patients. We have screened a panel of 100 off-patent licensed
oral drugs for anti-myeloma activity and identiﬁed niclosamide,
an anti-helminthic. Niclosamide, at clinically achievable non-
toxic concentrations, killed MM cell lines and primary MM cells
as efﬁciently as or better than standard chemotherapy and
existing anti-myeloma drugs individually or in combinations,
with little impact on normal donor cells. Cell death was
associated with markers of both apoptosis and autophagy.
Importantly, niclosamide rapidly reduced free light chain (FLC)
production by MM cell lines and primary MM. FLCs are a major
cause of renal impairment in MM patients and light chain
amyloid and FLC reduction is associated with reversal of tissue
damage. Our data indicate that niclosamides anti-MM activity
was mediated through the mitochondria with rapid loss of
mitochondrial membrane potential, uncoupling of oxidative
phosphorylation and production of mitochondrial superoxide.
Niclosamide also modulated the nuclear factor-jB and STAT3
pathways in MM cells. In conclusion, our data indicate that MM
cells can be selectively targeted using niclosamide while also
reducing FLC secretion. Importantly, niclosamide is widely
used at these concentrations with minimal toxicity.
Blood Cancer Journal (2011) 1, e39; doi:10.1038/bcj.2011.38;
published online 21 October 2011
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Introduction
Multiple myeloma (MM), a malignancy of differentiated B cells,
remains incurable. It is characterised by 410% neoplastic plasma
cells in the bone marrow, monoclonal immunoglobulin (Ig) in
serum and/or urine, lytic bone lesions and fractures, anaemia and
infection associated with immunodeﬁciency. Most patients also
develop renal impairment (RI) at some point during their disease
with 30% presenting with RI at diagnosis.
1–3 Several studies have
conﬁrmed that RI is associated with poor prognosis in MM with a
median survival of o2 years.
4–6 The causes of RI in myeloma are
multifactorial but predominantly attributable to nephrotoxic free Ig
light chains (FLC) secreted from the myeloma cell clone.
7 Reversal
of RI with high-dose dexamethasone (DEX)
8 combined with
bortezimib is a recommended treatment for MM patients with
any grade of RI
3 and induces rapid reduction in serum FLC levels
and associated renal recovery.
9
Improvements in survival outcomes in MM have been
achieved in the last three decades, especially in younger
patients. The development of high-dose melphalan with
autologous stem cell transplant for younger (o65 years) ﬁtter
patients
10–12 and new therapies incorporating combinations of
corticosteroids and conventional chemotherapy agents with
immunomodulatory drugs (thalidomide and lenalidomide), and
proteasome inhibitors (bortezomib) have increased median
survival to 4–5 years.
13–15 However, high-dose chemotherapy
and autologous stem cell transplant are not suitable for elderly
frail patients due to signiﬁcant toxicities. Approximately 85% of
myeloma patients are 460 years of age with a median age at
presentation of B70 years and median survival has remained
2–3 years in the over 70 cohort. Relapse with resistant disease is
a major cause of death in MM and although some agents used as
initial therapy (including thalidomide, lenalidomide and borte-
zomib) have shown activity and some improved outcomes in
patients with relapsed or refractory MM,
16–19 these responses
are usually of limited duration.
20 Consequently, effective non-
toxic therapies that provide either a cure or durable disease
control with symptomatic relief for elderly or relapsed/refractory
patients are urgently needed.
An alternative to new drug development is drug repositioning/
redeployment, the testing of existing compounds for efﬁcacy in
diseases other than those the drug is normally used to treat. The
use of thalidomide in myeloma and ATRA in acute promyelo-
cytic leukaemia are good examples of this. This approach
bypasses a signiﬁcant proportion of the cost of developing a
drug, the average pre-approval cost of developing a drug is over
800 million dollars,
21,22 and increases the speed that potentially
therapeutic discoveries in the laboratory can be translated into
the clinic. We have used a drug redeployment/reproﬁling
strategy to screen a library of 100 off-patent drugs/agents, at
clinically relevant peak serum concentrations, for anti-myeloma
activity against myeloma cell lines in vitro. The screen identiﬁed
niclosamide, a broad-spectrum anti-helminthic, as having
potent anti-myeloma activity against myeloma cell lines.
Importantly, niclosamide reduced the production of free light
chain production by both myeloma cell lines and primary
myeloma cells in vitro. These data highlight the therapeutic
potential of niclosamide in the treatment of MM and also other
paraproteinaemias.
Materials and methods
Drugs
All drugs were purchased from Sigma Aldrich (Dorset, UK).
Stocks were prepared at 10000  reported peak serum
concentrations and stored at  201C. Niclosamide (3.2mM),
prednisolone (716mM)
23 and chlorambucil (16.2mM)
24 were
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25 DEX (4.33mM),
26
cyclophosphamide (2 M),
27 thalidomide (109mM)
28,29 and
methotrexate (10mM)
30 were prepared in dimethyl sulfoxide.
Cell culture and drug treatments
JJN3, H929 and U266 cell lines were purchased from ATCC.
L363, OPM-1, RPMI 8226, LME-1, UM-1 and UM-3 were a kind
gift from Prof Pranab Das (University of Amsterdam, the
Netherlands). Stock cultures were maintained in RPMI 1640
medium with L-glutamine supplemented with 10% v/v heat
inactivated fetal bovine serum and penicillin (100units/ml)/
streptomycin (100mg/ml) (all from Gibco, Invitrogen Ltd,
Paisley, UK) at 371C with 5% CO2. Cells were passaged every
2–3 days maintaining cell densities between 0.5–2 10
6cells/
ml. Drug treatments in 96-well plate assays were performed
using 2 10
4cells/well in 200mlo ra t0 . 5 10
6cells/ml in 4ml
media in ﬂasks. Appropriate volumes of dimethyl sulfoxide and/
or ethanol were added as solvent controls to control treatments.
Measurement of cell viability
Cell viability was measured using one of three methods as
speciﬁed in the text. Numbers of viable cells in triplicate wells of
96-well plates were determined using CellTiter-Blue reagent
according to manufacturer’s instructions (Promega, Southampton,
UK). Viable cell counts were performed using manual counts, or
by ﬂow cytometry on a BD FACSCalibur utilising Cell Quest Pro
software (BD, Oxford, UK), viable gates and ﬂuorescent
Cytocount beads (Dako, Ely, UK).
Assessment of apoptosis by annexin V, cell cycle and
caspase cleavage
All analyses were carried out by ﬂow cytometry on a BD
FACSCalibur utilising Cell Quest Pro software (BD). Apoptosis
was assessed using an annexin V FITC kit (BD) and
a pan-caspase assay kit (CaspaTag, Chemicon, Millipore,
Watford, UK) according to manufacturer’s instructions. Cell
cycle was analysed by resuspending cell pellets from 500ml cell
suspensions in 500ml cell cycle buffer (30mg/ml proteasome
inhibitor, 0.1mM sodium chloride, 1% sodium citrate, 1%
Triton X100) and incubating at 41C for 4h before ﬂow
cytometric analysis.
Assessment of reactive oxygen species and
mitochondrial superoxide (mitosox)
MitoSOX Red (Molecular Probes, Invitrogen, Paisley, UK) was
used to assess mitosox. PBS-washed cells were resuspended in
200ml3 7 1C PBS containing 5mM MitoSOX Red, incubated at
371C for 10min and then analysed by ﬂow cytometry (emission
wavelength 580nm). Reactive oxygen species (ROS) was
measured using carboxy-H2DCFDA (5-(and-6)-carboxy-2’,7’-
dichlorodihydroﬂuorescein diacetate; Molecular Probes). Cells
were treated with drugs at 371C and 10mM carboxy-H2DCFDA
(Molecular Probes) added to 0.5ml cell suspension for the ﬁnal
45min. Following incubation, cells were analysed by ﬂow
cytometry (emission wavelength 517–527nm) (BD FACSCalibur
and BD Cell Quest software). For real-time measurement of
mitosox and ROS generation, cells were pre-labelled with
MitoSOX Red or carboxy-H2DCFDA. Baseline ROS or mitosox
was measured by ﬂow cytometry, the drug was added and then
measurements were taken at speciﬁed time intervals.
Measurements of mitochondrial membrane potential (Dc)
5,50,6,60-tetrachloro-1,10,3,30-tetraethylbenzimidazolylcarbo-
cyanine iodide (JC-1; Sigma Aldrich) was dissolved at 1mg/ml in
dimethyl sulfoxide and stored at  201C. Following treatment,
cells were incubated with 2.5mg/ml JC-1 at 371C for 30min,
before analysis by ﬂow cytometry. TMRE (tetramethylrhoda-
mine, ethyl ester) was prepared as a 20mM stock in dimethyl
sulfoxide. Cells were labelled in media with 10nM TMRE for
10min and then analysed by ﬂow cytometry.
Measurement of respiration rates
A Clark oxygen electrode (Rank Brothers Ltd, Cambridge, UK)
was used to measure respiration rates according to the
manufacturer’s instructions and data recorded using a chart
recorder. Brieﬂy, the incubation chamber was ﬁlled with
1300ml fresh RPMI 1640 media with supplements and the
readout calibrated at 100% O2 at 371C. Cells (50 10
6)i n
200ml of RPMI 1640 media with supplements were injected into
the incubation chamber and basal respiration rate recorded until
60% O2 remained. Subsequently, niclosamide (3.2mM) or the
classical oxidative phosphorylation uncoupler p-triﬂuoro-
methoxy carbonyl cyanide phenyl hydrazone (Sigma) (6.7mM)
was injected into the incubation chamber and the respiration
rate was recorded until 0% O2 was achieved. Gradients of
oxygen depletion were measured and respiration rates calcu-
lated as mmol molecular O2/10
6 cells/min assuming 100%
O2¼0.257mmol O2/ml at 371C.
FLC measurement in the supernatants of MM cells
FLC levels in the supernatants of MM cell lines were measured
using mouse monoclonal antibodies speciﬁc for free Igk or
l light chains (Freelite assay, Binding Site, Birmingham, UK
31)
in a Bio-Plex suspension array system (Bio-Plex HTF System,
Bio-Rad, Hercules, CA, USA). Cells of interest were washed with
media, seeded in fresh media into 96-well plates at a density of
50 10
3 cells/well, treated with appropriate agents and
incubated at 371C with 5% CO2. DEX served as a positive
control as it has been shown to decrease the production of
FLCs.
32,33 After incubation, supernatant from 150ml of cells was
used to determine light chain production. Cell viability was
assessed in a second 150ml aliquot of cells using Cytocount
beads (Dako) and ﬂow cytometry. Ig production was normalised
to viable cell number.
Western blot analyses
Cells were lysed in RIPA buffer (1% v/v NP40, 0.5% w/v sodium
deoxycholate, 0.1% w/v 10% SDS, protease inhibitors) and
30mg proteins separated by SDS-polyacrylamide gel electro-
phoresis. Proteins were transferred to Immobilon-P membrane
(Millipore Corp., Bedford, MA, USA) and probed with 1/1000
dilution of anti-LC3 antibody (Novus Biologicals, Cambridge,
UK). Detection was by anti-mouse-horse radish peroxidise
(Sigma) diluted 1/1000 and ECL using Supersignal Dura
Chemiluminescent substrate (Pierce, Rockford, IL, USA). Anti-
b-actin antibody (Sigma) diluted 1/25000 and anti-mouse-horse
radish peroxidise secondary at 1/25000 were used as loading
control. STAT3 levels were measured using mAb anti-STAT3
(BD) and anti-pY705-STAT3 (Cell Signalling Technologies,
Hitchin, UK) antibodies.
Real-time PCR quantiﬁcation
Reactions were performed using an ABI Prism 7700 sequence
detector (Applied Biosystems, Life Technologies Ltd, Paisley,
UK). Gene-speciﬁc primers were synthesised by Sigma Genosys
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UK). Igk forward primer: 50-CACACTGGCCTCCGATCAC-30,
Igk reverse: 50-TGCAGCCACAGTTCGTTTAATC-30;I g l forward:
50-CCACCAAACCCTCCAAACAG-30,I g l reverse: 50-GGGC
GTCAGGCTCAGGTA-30 (k probe: 6-FAM-TTCGGCCAAGGG
ACACGACTG-TAMRA; l probe: 6-FAM-CAACAACAAGTAC
GCGGCCAGCAG-TAMRA). Each reaction contained 900nM
of gene speciﬁc 50 and 30 primers, 1  Mastermix (Eurogentec),
125nM gene-speciﬁc probe (50-60-FAM, 30-TAMRA labelled) and
cDNA in a total volume of 20ml. Internal standard control 18S
ribosomal RNA reactions contained 50nM 18S 50 and 30 primers,
200nM 18S probe (50-VIC, 30-TAMRA labelled; Applied
Biosystems) and cDNA in a total volume of 20ml. Cycle
conditions for the thermal cycler were denaturation at 951C and
annealing and elongation at 601C for 1min, repeated 44 times.
Jenner Giemsa staining of cytospin cell preparations
Cytospins were prepared from 75 to 100ml of culture. Slides
were air dried, methanol ﬁxed and stained, 5min with Jenner
staining solution (VWR, Lutterworth, UK) diluted 1/3 in 1mM
sodium phosphate buffer pH 5.6, washed with distilled water
and then10min with Giemsa stain (VWR) diluted 1/20 in 1mM
sodium phosphate buffer, pH5.6. Slides were dried and then
mounted onto coverslips using DePex (VWR).
Statistics
Data were analysed using SPSS v15 (IBM, Portsmouth, UK) and
the non-parametric Mann–Whitney U-test or analysis of
variance. Unless stated in the legend, the statistics shown in
ﬁgures are all compared to control cultures.
Results
Drug screening identiﬁes niclosamide as being as
efﬁcient as common chemotherapeutics at killing
myeloma cells
The viability of three myeloma cell lines, H929, JJN3, U226,
was assessed following 72h treatments with a panel of 100
drugs (Drug Library FMC1) (Supplementary Figure 1). The library
was compiled by selecting oral, off-patent drugs of low toxicity
from all 15 chapters of the British National Formulary.
Importantly, each drug was used at the maximum peak serum
concentrations achieved as reported in the literature following
use for standard clinical indications. Of the 100 drugs,
niclosamide, an anti-helminthic, demonstrated potent anti-
proliferative activity against all three myeloma cell lines
(Supplementary Figure 1). The anti-proliferative actions of
niclosamide proved to be as effective as, if not more than,
reported peak serum concentrations of several common
chemotherapy (oral methotrexate, chlorambucil) and anti-
myeloma drugs (prednisolone, cyclophosphamide, DEX and
thalidomide) included in the library (Figure 1a).
Using a larger panel of eight myeloma cell lines and four
primary MM bone marrow samples (MM1-4), the anti-prolif-
erative effect of niclosamide at peak serum concentration
(3.2mM) was compared with the anti-myeloma drug combina-
tions of melphalan/prednisolone/thalidomide (MPT) and cyclo-
phosphamide/thalidomide/DEX (CTD). As shown in Figure 1b,
the drug combinations had variable anti-proliferative activity
against the eight cell lines with MPT being the more potent. In
contrast, all the cell lines displayed marked sensitivity to 3.2mM
niclosamide. All of the four primary MM samples demonstrated
sensitivities to niclosamide that were at least equivalent to MPT
if not better, with CTD being the least potent in these in vitro
assays. All the cell lines and primary MM samples demonstrated
dose-dependent responses to niclosamide, with 1mM niclosamide
being as potent in vitro as CTD and MPT in many of the myeloma
cell lines (Supplementary Figures 2 and 3). The dose and time
dependency of the niclosamide response of JJN3, U266 and
H929 cells are shown in Figure 1c. As early as 18h after addition
o fd r u g ,s i g n i ﬁ c a n tl o s so fv i a b i l i t yw a so b s e r v e dw i t ha sl i t t l ea s
1mM niclosamide (H929: 69.0%, JJN3: 72.1%, U266: 74.9%,
Po0.05). These decreases in viability became more apparent at
42h in H929 and JJN3 (H929: 45.9%, JJN3: 32.7%, U266:
77.7%, Po0.05) and in all three lines at 66h (H929: 8.4%, JJN3:
3.5%, U266: 57.1%, Po0.05). Importantly, niclosamide at doses
that impacted signiﬁcantly on MM cell survival (0.5 and 1.0mM)
did not affect the viability of normal donor PBMCs, with no affect
on the number of monocytes, B lymphocytes, C4 and CD8 T cells
over a 7-day period (Supplementary Figure 4). These data
indicate that all three myeloma cell lines were sensitive to doses
of niclosamide that are likely to be clinically achievable using
standard treatment regimens and that are unlikely to impact upon
normal healthy PBMCs.
The anti-myeloma activity of niclosamide is associated
with markers of apoptosis and autophagy
Flow cytometry analysis identiﬁed a clear dose-dependent
increase in annexin V positive and annexin V/propidium iodide
co-positive cells in the three myeloma cell lines analysed
(Figure 2a). In parallel, analysis of caspase activity using a
ﬂuorescent pan-caspase assay and ﬂow cytometry identiﬁed a
similar dose-dependent increase in caspase activity following
niclosamide treatment for 48h (Figure 2b). These data indicate
that niclosamide treatment induced apoptosis in myeloma cell
lines. However, despite the accumulation of annexin V positive
cells following treatment with niclosamide and the activation of
caspases, no major increase in the cell cycle sub-G1 fraction
(M3), which is indicative of DNA cleavage and cellular
fragmentation during apoptosis, was observed (Figure 2c).
Similarly, morphological analysis of cytospin preparations of
niclosamide-treated cells did not identify signiﬁcant numbers of
cells with classical hallmarks of apoptosis including condensed
fragmented nuclei and shrunken cells (Figure 2d). Instead, the
cells appeared enlarged, vesicular and collapsed upon prepara-
tion of the cytospins suggesting fragile plasma membranes. As
niclosamide has been demonstrated to induce autophagy in
MCF-7 cells,
34 we measured the levels of the autophagosome-
associated protein LC3-II in JJN3 cells treated with solvent
control or niclosamide for 24h. Western blot analysis identiﬁed
a clear increase in LC3-II levels in niclosamide-treated cells
consistent with induction of autophagy (Figure 2e). Thus
niclosamide induces cell death in myeloma cells with markers
of both apoptosis and autophagy.
Inhibition of FLC production
Given the clinical importance of reducing FLC levels for
reducing renal damage, we measured the impact of niclosamide
on FLC production. All myeloma cell lines were initially
assessed for their FLC secretion. Four lines were identiﬁed as
Igk secretors (JJN3, UM3, LME-1 and H929) and three as Igl
secretors (L363, RPMI 8226 and U226) and two were non-
secretors (OPM1 and UM1) (Supplementary Figure 5). JJN3 and
UM3 cell lines were selected as strong Igk secretors and L363
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supernatant was assessed following treatment with niclosamide
and compared with 5mM DEX. As shown in Figure 3a, 18h
treatment with niclosamide at either 0.5 or 1mM decreased Igk/l
secretion in all cell lines tested by between 15–60%.
Furthermore the ability of niclosamide to reduce Igk/l secretion
compared favourably with that of 5mM DEX, which reduced
secretion only in UM3 and RPMI 8226 cells by B20%
(Figure 3a). To determine whether the reduction in extracellular
FLC was as a result of reduced transcription, translation or
export, we measured the intracellular protein and mRNA levels
of Ig using indirect intracellular ﬂow cytometry and quantitative
real-time PCR, respectively. Following 18h treatment with 1mM
niclosamide signiﬁcant decreases were observed in intracellular
FLC protein levels in both cell lines analysed (JJN3: Igk: 38%
and L363: Igl: 23%, Po0.05) (Figure 3b). This correlated with a
signiﬁcant (B20%) reduction in Igk mRNA levels in JJN3
suggesting reduced FLC secretion was due in part to transcrip-
tional regulation by niclosamide (Figure 3c). In contrast, Ig
mRNA levels in the other lines were variable with both
decreases and increases observed in response to niclosamide
or DEX (Figure 3c). Importantly, niclosamide (1mM) also reduced
Ig protein levels in the supernatant of 6/9 primary myeloma cells
after 18h. Interestingly, 5/5 Igk myelomas had reduced levels of
FLC whereas only 1/4 of the Igl myelomas responded
(Figure 3d). The drug combinations of MPT also reduced Ig
secretion in 5/9 primary MM and CTD in 5/9 samples but not to
the same extent as niclosamide (Figure 3d).
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Figure 1 Niclosamide has potent anti-myeloma activity at peak serum concentrations. (a) H929, JJN3 and U266 cells were treated with peak
serum concentrations of a library of 100 drugs for 72h. Viability was assessed using CellTiter Blue (Promega) and calculated as percentage of
control. Myeloma cell line responses to the commonly used anti-myeloma therapeutics prednisolone (71.6mM), oral methotrexate (1mM),
dexamethasone (0.43mM), cyclophosphamide (200mM), chlorambucil (1.62mM), thalidomide (10.9mM) and the anti-helminthic niclosamide
(3.2mM) are shown. Data are the mean of three experiments±s.e.m. (b) A panel of eight myeloma cell lines were treated for 72h with two currently
used anti-myeloma combinations MPT (melphalan 10mM/prednisolone 71.6mM/thalidomide 10.9mM) or CTD (cyclophosphamide 200mM/
thalidomide 10.9mM/dexamethasone 0.43mM), and niclosamide at 3.2mM. Viability was assessed using CellTiter Blue (Promega) and calculated as
percentage of control. Data are the mean of a minimum of three experiments±s.e.m. Primary myeloma bone marrow samples (MM1-4) were also
treated as for the cell lines but for 48h. Viability was assessed by CD138/38 and annexin V staining and ﬂow cytometry. (c) H929, JJJN3 and U266
cells were treated with different doses of niclosamide at different timepoints and viability assessed by ﬂow cytometry using viable cells gates and
Cytocount beads. Data are the mean of three experiments±s.e.m.; *Po0.05.
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potential and uncouples oxidative phosphorylation in
myeloma cells
Uncouplers of oxidative phosphorylation (OXPHOS) function
by uncoupling the electron transport chain from ATP produc-
tion, usually by increasing the proton permeability of the
mitochondrial membrane thereby decreasing the proton elec-
trochemical potential (Dp). These results in a compensatory
increase in respiration rate as cells attempt to re-establish the
Dp. Classical OXPHOS uncouplers include p-triﬂuoromethoxy
carbonyl cyanide phenylhydrazone (FCCP) and carbonyl
cyanide m-chlorophenyl hydrazone (CCCP), which are
lipid-soluble weak acids. As, niclosamide is a weak acid and
has been shown to uncouple OXPHOS in tapeworms
35 and
human cells,
36,37 we tested for this activity in myeloma cells.
Treatment of H929 and JJN3 myeloma cells with niclosamide
resulted in loss of mitochondrial membrane potential (Dc)a s
measured using the Dc sensitive dyes JC-1 and TMRE (Figures 4a
and b). Loss of Dc was rapid being detected within 1min using
TMRE (Figures 4b and c). Loss of Dc in niclosamide-treated cells
was further conﬁrmed using the Dc-sensitive mitochondrial stain
Mitotracker Red (data not shown). A concomitant increase in
respiration rate following niclosamide-induced loss of Dc was
observed in all myeloma cell lines tested, to a similar extent as
Figure 2 Niclosamide-treated myeloma cells die with markers of apoptosis and autophagy. H929, JJN3 and U226 were treated with different
concentrations of niclosamide (Nic) for 48h. Cells were analysed by ﬂow cytometry for (a) annexin V/propidium iodide positivity (b) and caspase
activity using Caspatag assay according to manufacturer’s instructions. Data shown are the mean of three experiments±s.e.m. Representative
dotplots are shown for each assay; *Po0.05. (c) Cell cycle was analysed by staining cells with propidium iodide and ﬂow cytometry after treatment
with Nic for 24h. Representative histograms are shown for H929 cells. (d) Representative images are shown of Jenner/Giemsa-stained cytospins
from H929 and JJN3 cells treated with solvent control or Nic for 48h. (e) A volume of 30mg total protein from JJN3 cells treated with Nic for 24h
was immunoblotted for LC3-II protein. Image shown is representative of n¼2 experiments.
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Supplementary Figure 6) with increased respiration observed
within 5s of addition of the drug. These data indicate that the
mitochondria are a major target for niclosamide in myeloma cells.
Generation of mitochondrial superoxide correlates with
loss of cell viability
We next measured generation of ROS using carboxy-H2DCFDA
and mitochondrial superoxide using MitoSOX Red and ﬂow
cytometry. JJN3 and H929 myeloma cells were labelled
with each dye, baseline readings were taken using ﬂow
cytometry and then after the addition of 3.2mM niclosamide at
the times shown in Figure 5a. There was a rapid time-dependent
increase in mitochondrial superoxide generation in both
cell lines, evident in H929 cells within 15s of the addition of
niclosamide and within 60s in JJN3 cells (Figure 5a). The levels
of mitochondrial superoxide continued to increase signiﬁcantly
during the 20min of the experiment. In contrast, there was a
small initial increase in ROS levels (B2 fold) after the addition
of niclosamide to the cells and then no further elevation over the
duration of the experiment (Figure 4a).
The induction of mitochondrial superoxide was both niclo-
samide dose and time dependent (Figure 5b). In all three cell
lines, albeit with different kinetics, niclosamide at concentra-
tions as low as 1mM was able to induce signiﬁcant increases in
mitochondrial superoxide. In JJN3 and H929 this increase
occurred within 18h whereas in U266, which is a much slower
growing line, the increase was seen later (Figure 5b). Analysis of
other ROS species using carboxy-H2DCFDA identiﬁed no
Figure 3 Niclosamide reduces FLC from myeloma cell lines and primary MM samples. (a) MM cell lines were treated in 96-well plates for 18h
with either solvent control, 0.5–1.0mM niclosamide or 5mM dexamethasone. Supernatants were harvested and FLC measured using FreeLite assay.
FLC secretion was normalised for cell viability (data not shown). Nm¼not measured as there was signiﬁcant loss of viability. Data shown are the
mean of n¼3 experiments±s.e.m. (b) JJN3 and L363 cells were treated for 18h with either solvent control or 1.0mM niclosamide. Cells were
washed, ﬁxed and permeabilised and intracellular Ig detected using indirect staining and ﬂow cytometry. Isotype matched control antibodies were
used to control for non-speciﬁc binding. Data shown are the mean of n¼3 experiments±s.e.m. (c) Ig mRNA levels were measured after 18h
treatment using quantitative real time PCR and normalised to 18S internal standards. Data shown are the mean of n¼4 experiments±s.e.m.;
Po0.05. (d) Primary MM bone marrow-derived total mononuclear cells were treated in 96-well plates for 18h with MPT (melphalan 10mM/
prednisolone 71.6mM/thalidomide 10.9mM) or CTD (cyclophosphamide 200mM/thalidomide 10.9mM/dexamethasone 0.43mM), or niclosamide at
1mM. The supernatant was harvested and FLC levels measured using Luminex analysis. *Po0.05.
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at any of the timepoints analysed (Figure 5b) demonstrating that
mitochondrial superoxide is the main ROS species generated.
Cell viability was also assessed in parallel and demonstrated a
strong negative correlation with mitochondrial superoxide
generation (Figure 5c). Taken together these data strongly
implicate that the generation of mitochondrial superoxide
mediates the cytotoxicity of niclosamide against myeloma cell
lines.
Niclosamide regulates multiple cellular pathways
important for myeloma cells
Niclosamide has been demonstrated to regulate nuclear factor-
kB (NF-kB)
38 and STAT3 signalling.
39 Both of these pathways
are important players in myeloma pathogenesis and develop-
ment of chemoresistance.
40–42 We treated UM3 cells with 1mM
niclosamide for 2h and then stimulated them for 15min
with 100ng/ml tumour necrosis factora (TNFa). Sub-cellular
localisation of the p65 NF-kB subunit was assessed using
immunoﬂuorescence staining and ﬂuorescence microscopy.
As can be seen in Figure 6a, TNFa treatment resulted in nuclear
localisation of the p65 NF-kB subunit. This nuclear localisation
was signiﬁcantly inhibited by niclosamide treatment indicating
that niclosamide can regulate the canonical NF-kB pathway in
myeloma cells. It has also been shown that NF-kB signalling is
essential for mediating Igk, but not Igl, FLC transcription,
43
which may explain the reduction of Igk mRNA in JJN3 and UM3
MM cells and the preferential reduction of Igk mRNA in primary
MM cell described above (Figure 3c). Hence, we treated JJN3
cells with either niclosamide (1mM), TNFa (10ng/ml) or the
combination for 18h and measured the Igk mRNA levels and
protein secretion. As demonstrated previously (Figure 3c),
niclosamide reduced Igk mRNA levels B20% from controls.
Co-treatment with TNFa abrogated the effects of niclosamide
(Figure 6b). Importantly, TNFa was not able to restore FLC
secretion from niclosamide-treated JJN3 cells (Figure 6c) in-
dicating that niclosamide predominantly acts post-transcription-
ally in reducing FLC levels thereby explaining its activity against
both Igk and Igl secretors.
STAT3 is an important anti-apoptotic pathway in myeloma
and is activated by interleukin 6, which is induced by NF-kB.
44
Niclosamide has been shown to be a small molecule inhibitor of
STAT3 speciﬁcally preventing phosphorylation at tyrosine 705
(Y705) in a number of haematological malignancies.
39 Total
STAT3 and STAT3 pY705 levels were measured in JJN3 cells
pre-treated with 1 or 2mM niclosamide for 2h before activation
of the STAT3 signalling pathway with interleukin 6 for 15min.
As can be seen in Figure 6d, niclosamide inhibited interleukin
6-induced phosphorylation of STAT3 Y705 phosphorylation in a
dose-dependent manner with 2mM completely inhibiting detec-
tion of phosphorylated Y705. Hence, niclosamide may induce
cell death in myeloma cells in part by inhibiting STAT3
activation.
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We have demonstrated the potential therapeutic activity of
niclosamide against MM both at the level of cell killing and
diminution of FLC secretion and that these actions are mediated
by mitochondrial disruption and interference in both NF-kB and
STAT3 signalling. Niclosamide is an FDA-approved salicylani-
lide anti-helminthic used in the treatment of intestinal tapeworm
infections.
45 It has low toxicity in mammals (oral LD50 in rats,
45000mg/kg
46,47) and is inexpensive and readily available.
Taken orally, niclosamide exerts its anti-parasitic activity in the
intestinal lumen and although it has limited absorption capacity
(B10%), micromolar concentrations are achieved in serum after
a single oral dose in animals or humans.
46,48 Higher concentra-
tions of B25mM were achieved in rats with intravenous
application.
47 The peak serum concentration used in our initial
screen was 3.2mM.
46 At this concentration signiﬁcant anti-
proliferative activities were identiﬁed in all the MM cell lines
tested. Indeed, signiﬁcant anti-proliferative actions could be
detected at concentrations as low as 0.5–1.0mM in dose-
response experiments (Supplementary Figure 2). Niclosamide
at similar concentrations, has also been reported to reduce the
viability of acute myeloid leukaemia cell lines and primary AML
cells without impacting upon the survival of normal CD34þ
haemopoietic stem cells.
38 Similarly we have shown here that
niclosamide at doses that are active against MM cells have little
affect against PBMCs. Together these ﬁndings indicate that
niclosamide is unlikely to impact upon normal cells within the
therapeutic range that elicits anti-myeloma activity and is
therefore unlikely to be signiﬁcantly myeloablative or immuno-
suppressive.
Secretion of FLC protein by MM plasma cells is a common
feature of MM that frequently causes kidney tubule cast
nephropathy and renal failure and accounts for signiﬁcant
morbidity and mortality.
1,49 Renal impairment by monoclonal
FLC secretion may also be caused by amyloid deposits as in
monoclonal Ig deposition disease and light chain (AL) amyloi-
dosis. The severity of RI is associated with poorer prognosis and
rapid reversal of RI with improved survival.
3,9 Our study
demonstrated that low micromolar doses of niclosamide
reduced both Igk and Igl light chain protein production by
myeloma cell lines and primary myelomas in vitro (Figures 3a
and d). When compared with DEX (a drug clinically used to
reduce levels of light chains in MM and other diseases
3,33)o r
chemotherapy combinations (MPT, CTD), niclosamide was
equally if not more potent (Figure 3). We evaluated whether
the actions of niclosamide were transcriptional, possibly
through modulation of NF-kB as NF-kB is known to regulate
Figure 6 Niclosamide inhibits both the NF-kB and STAT3 pathways in myeloma cells. (a) UM3 cells were treated with either solvent control or
1mM niclosamide before the addition of 100ng/ml TNFa for 15min. Cytospins were prepared, ﬁxed with paraformaldehyde, stained for NF-kB p65
(red) and counterstained with Hoechst 33342 for DNA. Images are representative of triplicate experiments. (b) JJN3 cells were treated overnight
with either solvent control, 1mM niclosamide and/or 10ng/ml TNFa. RNA was extracted from cells and Igk levels measured by quantitative real-
time PCR. Data shown are mean from n¼4 experiments±s.e.m. (c) Supernatant was also harvested from JJN3 cells and secreted FLC protein levels
measured by Luminex. Data shown are mean from n¼4 experiments±s.e.m.; *Po0.05. (d) JJN3 cells were pretreated with niclosamide at either
1o r2mM for 2h before the addition of 1mg/ml interleukin 6 (IL6) for 15min. Total protein was extracted from cells and immunoblotted for total
STAT3 protein, Y705 phosphorylated STAT3 with b-actin as a loading control. Images are representative of n¼3 experiments.
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mide induced a reduction in Ig mRNA levels in the k secreting
JJN3 and UM3 cell lines but not in the l secreting RPMI8226
and L363 cell lines; (Figure 3c) however, TNFa treatment was
able to overcome this transcriptional inhibition in UM3 cells
(Figure 6b). TNFa treatment was not able to abrogate the
niclosamide-mediated reduction in Igk FLC protein secretion in
UM3 cells (Figure 6c). This data combined with the observed
reductions in intracellular Ig protein in the k secreting JJN3 line
and l-secreting L363 line (Figure 3b) indicate that niclosamide
is acting post-transcriptionally.
The loss of viability of MM cells following niclosamide
treatment was associated with markers of both apoptosis and
autophagy. Autophagy is a lysosomal pathway responsible for
the breakdown of cytoplasmic contents in nutrient-starved cells
and is therefore a survival mechanism. In contrast, under certain
circumstances autophagic cells may undergo a speciﬁc mode of
cell death called type II cell death or autophagic cell death.
Mammalian target of rapamycin complex 1 (mTORC1) is a
critical regulator of autophagy by coupling nutrient sensing to
anabolic and catabolic cellular processes.
50 When nutrients are
available, mTORC1 is switched on and negatively regulates
autophagy.
51 Conversely, nutrient limitation turns off mTORC1
signalling, leading to inhibition of cell growth and stimulation of
autophagy. Rapamycin, an irreversible inhibitor of mTORC1,
and other rapalogs are under investigation in MM and other
haematological malignancies.
52,53 Balgi et al.
34 identiﬁed
niclosamide as an inhibitor of mTORC1 using a high-throughput
screen. These and our data indicate that niclosamide is able to
induce autophagy in multiple cancer cell models.
Niclosamide has been demonstrated to regulate multiple
cellular pathways including the NF-kB,
38 STAT3,
39 WNT/
frizzled1,
54–56 mTORC1
(ref.34) and NOTCH
57 signalling path-
ways. Our data demonstrated that niclosamide is able to affect
at least two of the described pathways, which are known to be
important in myeloma, the NF-kB pathway and STAT3 signal-
ling (Figure 6). However, we would argue that the major target
of niclosamide is the mitochondria. Niclosamide has been
demonstrated to uncouple OXPHOS in other human cells
36,37
and induce ROS production in AML cells.
38 Niclosamide
treatment of myeloma cells resulted in rapid loss of mitochon-
drial membrane potential (Dc), with an associated increase in
respiration rate consistent with uncoupling of OXPHOS
(Figure 4). These changes were associated with the rapid
generation of mitochondrial superoxide rather than other ROS
species. Furthermore, the generation of mitochondrial super-
oxide correlated signiﬁcantly with loss of MM cell viability
indicating a critical role for mitochondrial superoxide in
niclosamide action (Figure 5). Consistent with this, mitochon-
drial function is known to regulate both apoptosis and
autophagic cell death.
58–60 Further, Chen et al.
58 demonstrated
that superoxide, and not other ROS species, is a major regulator
of autophagy.
In conclusion, our data indicate that MM cells can be
selectively targeted using niclosamide, a drug, which targets the
mitochondria and consequently many of the key pathways in
myeloma, although also reducing FLC secretion. Importantly,
niclosamide is inexpensive, available and likely to have low
in vivo toxicity.
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